Five things for pharma marketers to know:
- The Centers for Medicare and Medicaid Services announced plans to broadly cover a new class of Alzheimer’s drugs pending approval by the Food and Drug Administration.
- Sandoz said it plans to move to a new central Basel headquarters by mid-2024 following its proposed spin-off from Novartis.
- Eikon Therapeutics announced three business development deals, effectively dropping in a pipeline of cancer drugs alongside more than $100 million in fresh funding.
- AstraZeneca and Merck’s Lynparza gained an expanded prostate cancer indication from the FDA.
- The Supreme Court gave a boost to whistleblowers in their bid to revive lawsuits accusing pharmacy operators of knowingly overbilling government health insurance programs for prescription drugs at taxpayers’ expense.
